Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc. boasts a proprietary metagenomics-derived genome editing toolbox that enables precise therapeutic interventions, showcasing promising advancements in treating genetic disorders through its pipeline, including Hemophilia A and other significant conditions. The company's gene editing approach has demonstrated impressive durability, achieving FVIII levels of 80% at the 19-month mark in preclinical models, highlighting its potential for long-term therapeutic effectiveness. Additionally, Metagenomi's dual focus on in vivo gene editing and technology out-licensing for ex vivo cell therapy positions the company favorably to capitalize on the growing demand for innovative genetic medicines.

Bears say

Metagenomi Inc reported a notable net loss of $19.9 million for the second quarter of 2025, equating to a loss of $0.54 per share. The company faces significant risks that could adversely affect its financial prospects, including potential delays in advancing pipeline candidates through clinical assessments, failure to produce favorable clinical data, especially for key programs such as Hemophilia A, and the risk of long-term dilution. Despite trading below its cash value, the combination of these risks contributes to a negative outlook for Metagenomi's stock performance.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Nov 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.